Biased research, aggressive sales, harmful drugs
The Health Policy Exchange
MAY 20, 2013
Although a 2007 meta-analysis first sounded the alarm about rosiglitazone's cardiovascular risks, the manufacturer successfully stalled regulatory action in the U.S. government agencies do more to protect patients from the effects of biased research and aggressive sales tactics for newly marketed drugs? Could the FDA and other U.S.
130 
Let's personalize your content